High-Dose Vitamin C for Burn Treatment: Study Halted
Investigating the Role of Vitamin C
Can high-dose Vitamin C alleviate the effects of severe burns? This question was the focus of a large-scale, placebo-controlled study led by an international research team. However, the study was abruptly terminated after its first interim analysis.
High-dose intravenous Vitamin C has been a topic of discussion in treating burn victims for decades. Previous smaller studies suggested that this treatment might reduce the volume of fluids required and the duration of mechanical ventilation for patients suffering from serious burns.
The VICTORY Study
In a significant effort, researchers, including Prof. Dr. Christian Stoppe from the University Hospital of Würzburg, conducted the VICTORY study. They aimed to measure hard combined endpoints: 28-day mortality and persistent organ dysfunction.
Persistent organ dysfunction was defined as ongoing dependence on mechanical ventilation, renal replacement therapy, or vasopressor/inotropic therapy after 28 days. Unfortunately, the initial interim analysis indicated that the outcomes were unlikely to be positive, leading to an immediate cessation of the study.
The Hypothesis Behind the Study
The underpinning hypothesis of the VICTORY study was that acute systemic inflammatory reactions following severe burns significantly contribute to organ failure and mortality rates. The researchers hoped that the antioxidant properties of Vitamin C could mitigate these pathophysiological processes and preserve organ functions.
Study Design and Participant Details
The phase-III study was international, multicenter, randomized, double-blind, and placebo-controlled, involving 238 participants aged 18 and older. These individuals suffered from deep second- or third-degree burns, affecting at least 20% of their total body surface area, and requiring skin grafts.
Severity and organ functions were assessed using established intensive care scores, such as the SOFA and APACHE II scores. Notably, more than half of the patients were already receiving invasive mechanical ventilation at the time of randomization.
Participants were administered either high-dose intravenous Vitamin C at a dosage of 50 mg/kg body weight every six hours for 96 hours or a placebo. This treatment was provided alongside standard intensive care measures, including fluid management, organ support, and surgical burn treatment.
Study Findings and Implications
The primary combined endpoint—28-day mortality and persistent organ dysfunction—occurred in 40.8% of patients in the Vitamin C group compared to 29.7% in the placebo group. This revealed no survival or organ function advantages associated with the Vitamin C treatment; in fact, there was a trend toward worse outcomes in those receiving Vitamin C.
Significantly, there was a higher mortality rate in the intervention group. While the 28-day mortality was 15.0% for the Vitamin C group, it was only 7.6% for the placebo group. Additionally, no evidence was found to support a reduction in hospital stay or improvement in other clinically relevant outcomes. The anticipated benefits regarding fluid requirements, organ functions, or recovery were not substantiated.
Conclusion
“Our study provides, for the first time, high-quality, randomized evidence regarding high-dose Vitamin C in severe burns,” stated Prof. Stoppe in a press release. “The therapy is ineffective and may even be harmful. Therefore, it should not be used routinely.”
This significant finding underscores the necessity for rigorous scientific evidence in evaluating treatment options for critical conditions like severe burns. Future research will continue to seek effective methods to manage such complex clinical scenarios.
